Skip to main content
Top
Published in: Diagnostic Pathology 1/2018

Open Access 01-12-2018 | Research

Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment

Authors: Essam Ayad, Ahmed Soliman, Shady Elia Anis, Amira Ben Salem, Pengchao Hu, Youhong Dong

Published in: Diagnostic Pathology | Issue 1/2018

Login to get access

Abstract

Background

Breast cancer is by far the most frequent cancer among women. The proliferative index, Ki-67, is more and more taken into consideration for treatment decisions. However, the reliability of the established Ki-67 scoring is limited. Digital pathology is currently suggested to be a potential solution to Ki 67 assessment problems.

Methods

This is a retrospective and prospective study including 100 patients diagnosed with invasive breast cancer. Three senior pathologists have been asked to estimate the Ki-67 proliferative index for each of the 100 cases by examining the whole glass slides on optical microscope and providing a continuous score then a categorical score (‘high’ and ‘low’ Ki 67 index) using once 14%, once 20% as threshold indicative of high Ki67 status. Finally, a digital quantitative assessment of Ki67 was performed.

Results

A high inter-observer agreement was found when using optical microscopy for Ki 67 assessment, with correlation coefficient (CC) estimated at 0.878 (p value < 0.01). The overall agreement between manual and automated evaluation of Ki 67 was only substantial (CC estimated at 0.745 (p value < 0.01)). When using categorical scores, the inter-observers concordance was substantial using both cutoff points with kappa value estimated at 0.796 ([0.696–0.925] while using 14% as a cut off point and at 0.766 ([0.672–0.938] while using 20% as a cutoff point (p value < 0). The inter-observers agreement was better while using 14% as cutoff point. Agreement between manual and automated assessment of Ki 67 indices using both cutoff points was only substantial (Kappa estimated at 0.623, p value < 0.01). In comparison to automated assessment of Ki 67 index, while using 14% as a cutoff point, the overall tendency of all observers was to overestimate the Ki 67 values but to underestimate the proliferation index while using 20% as a cutoff point.

Conclusion

Automated assessment of Ki 67 value would appear to be comparable to visual Ki 67 assessment on optical microscopy. Such study would help define the role of digital pathology as a potential easy-to use tool for a robust and standardized fully automated Ki 67 scoring.
Literature
2.
go back to reference American Cancer Society. Global Cancer Facts & Figures. 3rd ed. Atlanta: American Cancer Society; 2015. p. 37. American Cancer Society. Global Cancer Facts & Figures. 3rd ed. Atlanta: American Cancer Society; 2015. p. 37.
3.
go back to reference Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715–24.CrossRefPubMed Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715–24.CrossRefPubMed
4.
go back to reference Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110(3):565–72.CrossRefPubMed Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110(3):565–72.CrossRefPubMed
5.
go back to reference Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–64.CrossRefPubMedPubMedCentral Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–64.CrossRefPubMedPubMedCentral
6.
go back to reference Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132:895–915.CrossRefPubMed Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012;132:895–915.CrossRefPubMed
7.
go back to reference Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast Cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22:1736–47.CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast Cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22:1736–47.CrossRefPubMedPubMedCentral
8.
go back to reference Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentral
9.
go back to reference Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRefPubMedPubMedCentral
10.
go back to reference Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, et al. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. PLoS One. 2015;10(7):e0119565.CrossRefPubMedPubMedCentral Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, et al. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. PLoS One. 2015;10(7):e0119565.CrossRefPubMedPubMedCentral
11.
go back to reference Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, et al. Proposed new clinicopathological surrogate definitions of luminal a and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014;16:R65.CrossRefPubMedPubMedCentral Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, et al. Proposed new clinicopathological surrogate definitions of luminal a and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014;16:R65.CrossRefPubMedPubMedCentral
12.
go back to reference Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M. Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast Cancer. Ann Oncol. 2015;26:1533–46.CrossRefPubMedPubMedCentral Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M. Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast Cancer. Ann Oncol. 2015;26:1533–46.CrossRefPubMedPubMedCentral
13.
go back to reference Gnanta M, Harbeckb N, Thomssen C. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and De-escalation of primary breast Cancer treatment. Breast Care. 2017;12:102–7.CrossRef Gnanta M, Harbeckb N, Thomssen C. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and De-escalation of primary breast Cancer treatment. Breast Care. 2017;12:102–7.CrossRef
14.
go back to reference Weinstein RS, Graham AR, Richter LC, Barker GP, Krupinski EA, Lopez AM, et al. Overview of telepathology, virtual microscopy, and whole slide imaging: prospects for the future. Hum Pathol. 2009;40(8):1057–69.CrossRefPubMed Weinstein RS, Graham AR, Richter LC, Barker GP, Krupinski EA, Lopez AM, et al. Overview of telepathology, virtual microscopy, and whole slide imaging: prospects for the future. Hum Pathol. 2009;40(8):1057–69.CrossRefPubMed
15.
go back to reference Al-Janabi S, Huisman A, Van Diest PJ. Digital pathology: current status and future perspectives. Histopathology. 2012;61(1):1–9.CrossRefPubMed Al-Janabi S, Huisman A, Van Diest PJ. Digital pathology: current status and future perspectives. Histopathology. 2012;61(1):1–9.CrossRefPubMed
16.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed
17.
go back to reference Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33(3):613–9.CrossRef Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33(3):613–9.CrossRef
18.
go back to reference Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M. Fujisue1 M. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014;2:1062–8.CrossRefPubMedPubMedCentral Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M. Fujisue1 M. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014;2:1062–8.CrossRefPubMedPubMedCentral
19.
go back to reference Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol. 2014;67:222–8.CrossRefPubMed Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol. 2014;67:222–8.CrossRefPubMed
20.
go back to reference Tan QX, Qin QH, Yang WP, Mo QG, Wei CY. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvantchemotherapy. Int J Clin Exp Pathol. 2014;7(10):6862–70.PubMedPubMedCentral Tan QX, Qin QH, Yang WP, Mo QG, Wei CY. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvantchemotherapy. Int J Clin Exp Pathol. 2014;7(10):6862–70.PubMedPubMedCentral
21.
go back to reference Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212–20.CrossRefPubMed Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212–20.CrossRefPubMed
22.
go back to reference Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17(4):323–34.CrossRefPubMed Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17(4):323–34.CrossRefPubMed
23.
go back to reference Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012;7:e3737. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012;7:e3737.
24.
go back to reference Polley MYC, Leung SCY, McShane LM, Gao D, Hugh JC. Mastropasqua MG et al. An international Ki67 reproducibility study on behalf of the international Ki67 in breast Cancer working group of the breast international group and north American breast Cancer group. J Natl Cancer Inst. 2013;105(24):1897–906.CrossRefPubMedPubMedCentral Polley MYC, Leung SCY, McShane LM, Gao D, Hugh JC. Mastropasqua MG et al. An international Ki67 reproducibility study on behalf of the international Ki67 in breast Cancer working group of the breast international group and north American breast Cancer group. J Natl Cancer Inst. 2013;105(24):1897–906.CrossRefPubMedPubMedCentral
25.
go back to reference Shui R, Yu B, Bi R, Yang F, Yang W. An Interobserver reproducibility analysis of Ki67 visual assessment in breast Cancer. PLoS One. 2015;10(5):e0125131.CrossRefPubMedPubMedCentral Shui R, Yu B, Bi R, Yang F, Yang W. An Interobserver reproducibility analysis of Ki67 visual assessment in breast Cancer. PLoS One. 2015;10(5):e0125131.CrossRefPubMedPubMedCentral
26.
go back to reference Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors–a surrogate marker? Cancer. 2003;97(5):1321–31.CrossRefPubMed Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors–a surrogate marker? Cancer. 2003;97(5):1321–31.CrossRefPubMed
27.
go back to reference Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant Anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast Cancer—a study from the IMPACT Trialists. J Clin Oncol. 2005;23(11):2477–92.CrossRefPubMed Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant Anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast Cancer—a study from the IMPACT Trialists. J Clin Oncol. 2005;23(11):2477–92.CrossRefPubMed
28.
go back to reference Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between Letrozole, Anastrozole, and Exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast Cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype- ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.CrossRefPubMedPubMedCentral Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between Letrozole, Anastrozole, and Exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast Cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype- ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.CrossRefPubMedPubMedCentral
29.
go back to reference Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, et al. Standardization for Ki- 67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study. PLoS ONE. 2015;10(4):e0123435.CrossRefPubMedPubMedCentral Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, et al. Standardization for Ki- 67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study. PLoS ONE. 2015;10(4):e0123435.CrossRefPubMedPubMedCentral
30.
go back to reference Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–71.CrossRefPubMedPubMedCentral Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–71.CrossRefPubMedPubMedCentral
31.
go back to reference Soenksen D. Digital pathology at the crossroads of major health care trends: corporate innovation as an engine for change. Arch Pathol Lab Med. 2009;133:555–9.PubMed Soenksen D. Digital pathology at the crossroads of major health care trends: corporate innovation as an engine for change. Arch Pathol Lab Med. 2009;133:555–9.PubMed
32.
go back to reference Kayser K, Borkenfeld S, Kayser G. How to introduce virtual microscopy (VM) in routine diagnostic pathology: constraints, ideas, and solutions. Anal Cell Pathol. 2012;35:3–10.CrossRef Kayser K, Borkenfeld S, Kayser G. How to introduce virtual microscopy (VM) in routine diagnostic pathology: constraints, ideas, and solutions. Anal Cell Pathol. 2012;35:3–10.CrossRef
33.
go back to reference Mohammed ZMA, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, et al. Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer. 2012;106(2):383–8.CrossRefPubMedPubMedCentral Mohammed ZMA, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, et al. Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer. 2012;106(2):383–8.CrossRefPubMedPubMedCentral
34.
go back to reference Zhong F, Bi R, Yu B, Yang F, Yang W, Shui R. A comparison of visual assessment and automated digital image analysis of Ki67 labeling index in breast Cancer. PLoS One. 2016;11(2):e0150505.CrossRefPubMedPubMedCentral Zhong F, Bi R, Yu B, Yang F, Yang W, Shui R. A comparison of visual assessment and automated digital image analysis of Ki67 labeling index in breast Cancer. PLoS One. 2016;11(2):e0150505.CrossRefPubMedPubMedCentral
35.
go back to reference Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol. 2011;6(1):S7.CrossRefPubMedPubMedCentral Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol. 2011;6(1):S7.CrossRefPubMedPubMedCentral
36.
go back to reference Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18:104.CrossRefPubMedPubMedCentral Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18:104.CrossRefPubMedPubMedCentral
37.
go back to reference Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61:1134–44.CrossRefPubMed Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61:1134–44.CrossRefPubMed
38.
go back to reference Stålhammar G, Martinez NF, Lippert M, Tobin NP, Mølholm I, Kis L, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29:318–29.CrossRefPubMed Stålhammar G, Martinez NF, Lippert M, Tobin NP, Mølholm I, Kis L, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29:318–29.CrossRefPubMed
39.
go back to reference Suciu C, Muresan A, Cornea R, Suciu O, Dema A, Raica M. Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast. Oncol Lett. 2014;7(1):107–14.CrossRefPubMed Suciu C, Muresan A, Cornea R, Suciu O, Dema A, Raica M. Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast. Oncol Lett. 2014;7(1):107–14.CrossRefPubMed
Metadata
Title
Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment
Authors
Essam Ayad
Ahmed Soliman
Shady Elia Anis
Amira Ben Salem
Pengchao Hu
Youhong Dong
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2018
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-018-0735-7

Other articles of this Issue 1/2018

Diagnostic Pathology 1/2018 Go to the issue